Beyond deficiency:Potential benefits of increased intakesof vitamin K for bone and vascular health by Vermeer, C et al.
Eur J Nutr (2004) 43:325–335
DOI 10.1007/s00394-004-0480-4
Received: 30 June 2003
Accepted: 10 December 2003
Published online: 5 February 2004
C.Vermeer,PhD ( )
Dept.of Biochemistry,
University of Maastricht
P.O. Box 616
6200 MD Maastricht,The Netherlands
Tel.: +31-43/388-1682
Fax: +31-43/388-4159
E-Mail: c.vermeer@bioch.unimaas.nl
M.J.Shearer
St.Thomas’Hospital
London,UK
A.Zittermann
University of Bonn
Bonn,Germany
C.Bolton-Smith
MRC Human Nutrition Research
Cambridge,UK
P. Szulc
INSERM
Lyon, France
S.Hodges
University College London
London,UK
P. Walter
University of Basel
Basel,Switzerland
W. Rambeck
University of Munich
Munich, Germany
E.Stöcklin · P.Weber
Roche Vitamins Ltd.
Basel,Switzerland
This paper has been sponsored by an unre-
stricted education grant from Roche Vita-
mins Europe Ltd.
■ Summary Vitamin K is well
known for its role in the synthesis
of a number of blood coagulation
factors.During recent years vita-
min K-dependent proteins were
discovered to be of vital impor-
tance for bone and vascular health.
Recommendations for dietary vita-
min K intake have been made on
the basis of the hepatic require-
ments for the synthesis of blood
coagulation factors.Accumulating
evidence suggests that the require-
ments for other functions than
blood coagulation may be higher.
This paper is the result of a closed
workshop (Paris,November 2002)
in which a number of European
vitamin K experts reviewed the
available data and formulated their
standpoint with respect to recom-
mended dietary vitamin K intake
and the use of vitamin K-contain-
ing supplements.
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Beyond Deficiency:
Potential benefits of increased intakes 
of vitamin K for bone and vascular health
Introduction
Historically, compounds with vitamin K activity have
been classified according to the chemical structure of
the isoprenoid side chain at the 3-position of the 2-
methyl 1.4 naphthoquinone nucleus. The major natu-
rally occurring forms are phylloquinone (vitamin K1;
abbreviated K1), and menaquinones (vitamin K2).
Menaquinones can be further sub-classified,depending
on the length of their side-chain; the various forms are
denominated as menaquinone-n etc. (abbreviated to
MK-n), where n denotes the number of isoprenyl units
in its side chain. Menadione (vitamin K3) is a synthetic
compound lacking a side chain but is biologically active
by virtue of its conversion in the body to MK-4. The
most nutritionally relevant menaquinones are MK-4
and MK-7 through MK-9. In the human diet, K1 is pre-
dominantly found in leafy green vegetables and some
vegetable oils and margarines [1, 2], whilst MKs are
present in lower concentrations in meats,milk products,
and eggs (MK-4),as well as in animal livers,cheeses,and
natto (MK-5 to MK-13) [3].There is evidence that K1can
be endogenously converted to MK-4 [4].
In all cells that synthesise vitamin K-dependent pro-
teins, dietary-derived vitamin K quinone is reduced to
vitamin K quinol (KH2),which acts as a cofactor for the
posttranslational carboxylation of certain glutamate
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residues, producing gamma-carboxyglutamate (Gla).
Hence vitamin K-dependent proteins are also known as
Gla-proteins. During gamma-glutamyl carboxylation,
the KH2 cofactor is converted to vitamin K epoxide
(KO); this metabolite is then salvaged and recycled to
KH2 via vitamin K by the warfarin-sensitive vitamin K-
epoxide reductase (VKOR) [5].Apart from their classi-
cal role in blood coagulation, Gla-containing proteins
have a diversity of regulatory functions including blood
coagulation, bone turnover [6, 7], vascular repair
processes [8], the prevention of vascular calcification
[9],cell cycle regulation and cell-cell adhesion,and sig-
nal transduction [10].Vitamin K-deficiency will lead to
the production of under-carboxylated (i.e., inactive)
Gla-proteins, and thus to interference with the physio-
logical processes mentioned above. Thus far, recom-
mended levels of dietary vitamin K intake have been de-
fined on the basis of the hepatic requirement for normal
clotting factor synthesis. Accumulating evidence sug-
gests that other tissues,notably bone and arteries,need
higher vitamin K intakes for adequate carboxylation of
the locally produced Gla-proteins. This paper is based
on the proceedings from a closed workshop at which the
authors reviewed new and existing data on the anti-os-
teoporotic and cardio-protective properties of K-vita-
mins, with the aim of establishing whether higher in-
takes (from diet or supplements) than currently
recommended have appreciable health benefits. The
principal opinions and the conclusions reached repre-
sent those of the majority of the workshop panel.
How to monitor vitamin K status
When equimolar doses of K1,MK-4,and MK-9 (fat-sol-
ubilized pure compounds) are administered to healthy
people, the highest plasma levels are obtained after K1,
lower concentrations after MK-4 (but appearing more
rapidly),and still lower concentrations after MK-9.The
plasma half-life ofMK-9 is considerably longer than that
of the other forms [11]. Bioavailability studies indicate
that plasma levels attained after giving K1 supplements
are higher than those for equivalent amounts of dietary
K1 [3].In population studies,plasma K1 levels have been
shown to be positively [12] and linearly [13] correlated
with dietary K1 intakes,but with an apparent plateau of
plasma K1 at intakes>200 µg/day [13]. If administered
as pharmacological,detergent-solubilized preparations,
a linear dose-response relationship may continue to
very high intakes [14]. The vitamin K studies carried-
out in Dundee [15–17],and those from the UK National
Diet and Nutrition Surveys [12] demonstrated that vita-
min K intake was wide-ranging. The average intake in
the younger population was found to be around 70
µg/day, whilst in older subjects typical values were be-
tween 80–120 µg/day.Similar data were obtained in pop-
ulation-based surveys in the USA [18], whereas in The
Netherlands, a country with traditionally a high veg-
etable consumption, higher values were recorded [19].
These intake data alone cannot provide evidence of ad-
equacy.
Population surveys have indicated that between 5
and 15% of healthy subjects have undetectable serum
phylloquinone concentrations,suggesting that the vita-
min K status of such individuals may be sub-optimal,es-
pecially if under-carboxylation of non-coagulation Gla
proteins were shown to adversely influence health. Di-
rect measurement of serum vitamin K levels is influ-
enced by recent diet, and is prone to wide variations.
Since K vitamins are carried by lipoproteins and are cor-
related to plasma lipids, blood sampling for analysis
should be performed in subjects after an overnight fast.
Serum vitamin K may be regarded as an overall marker
for vitamin K status,and K1 values of 150–200 pg/ml are
considered to be the lower limit of the normal range
[12]. Even though serum concentrations of individual
menaquinones (MK-4 through MK-13) are generally be-
low the lower detection limit of current analytical meth-
ods, the combined menaquinone fraction may form a
substantial fraction of circulating and tissue vitamin K
stores. A gap in our knowledge is that the relative effi-
cacy ofmenaquinones as cofactors for the vitamin K-de-
pendent carboxylase in different cells and tissues re-
mains unclear.A potential alternative to serum vitamin
K as a measure of vitamin K status is provided by mea-
suring urinary vitamin K metabolites: both K1 and K2
vitamins are excreted in the urine as two side-chain-
shortened metabolites (5C and 7C) [20]. Theoretically,
analyses of these metabolites can help to define vitamin
K status,because they provide insight into total vitamin
K (K1+K 2) utilization. However, further studies are re-
quired to validate urinary metabolite excretion against
other indices of vitamin K status.
Valuable as they are,assays for serum and urine vita-
min K measurement do not provide information on ad-
equacy at the tissue level.Therefore,the direct measure-
ment of the gamma-carboxylation status of the
Gla-proteins produced in the tissue of interest is ideally
required.Since the Gla-coagulation proteins are synthe-
sized in the liver, assays for them are appropriate for
monitoring the hepatic vitamin K status.Severe vitamin
K-deficiency may be diagnosed from coagulation as-
says, but such tests are insensitive for subclinical defi-
ciency. Microtitre plate-based assays using conforma-
tion-specific monoclonal antibodies recognizing
under-carboxylated species of prothrombin provide an
alternative and sensitive tool for assessing hepatic vita-
min K status [21]. Osteocalcin (OC) is a small Gla-pro-
tein uniquely synthesized in bone, and circulating un-
der-carboxylated osteocalcin (ucOC) provides a
measure of the vitamin K status of bone [22].Population
studies suggest a correlation between the levels of circu-C. Vermeer et al. 327
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lating vitamin K, ucOC, and carboxylated osteocalcin
(cOC), and all three parameters should ideally be mea-
sured to provide an accurate indication ofvitamin K sta-
tus and function. The ratio between ucOC and cOC is
probably the most sensitive marker for bone vitamin K
status.A wealth of evidence demonstrates that usual di-
etary intakes of vitamin K in healthy adults (together
with an unknown fraction from bacterial synthesis of
MKs in the gut) are more than sufficient to ensure al-
most complete gamma-carboxylation of the hepatic
Gla-proteins involved in blood coagulation.However,it
is equally clear that the dietary intakes are insufficient to
ensure complete carboxylation of osteocalcin, around
10–30% of which (the values are assay specific) occurs
in an under-carboxylated state in the healthy adult pop-
ulation [23, 24].Whether this has physiological signifi-
cance with respect to bone health is presently unclear
but it is a matter of potential concern that elevated
serum ucOC was reported to correlate inversely with
bone mineral density of the hip, and to correlate posi-
tively  with hip fracture risk [22, 25, 26]. Population
ranges for ucOC/cOC ratios may be determined either
indirectly by using a differential binding assay to sepa-
rate cOC and ucOC species prior to immunoassay or di-
rectly by using conformation-specific antibodies,which
are available for both OC forms.Published values using
indirect binding assays vary widely and it is important
to standardise the many variables associated with this
type of assay and make appropriate corrections for the
basal level of OC [27].Although the direct assays appear
attractive,relatively little is known of the relative affin-
ity of the ucOC and cOC antibodies for intact OC and
the several OC fragments which may circulate either
naturally, or which may arise as a consequence of un-
derlying bone pathology or as artefacts due to inappro-
priate sample handling.Although ucOC is responsive to
increased dietary vitamin K, a maximal response has
only been achieved with pharmacological vitamin K in-
takes. For Gla proteins that are synthesised in tissues
other than liver and bone, new biomarkers need to be
developed. One Gla protein of major current interest is
matrix Gla-protein (MGP). This protein is mainly syn-
thesised by chondrocytes and vascular smooth muscle
cells; hence under-carboxylated forms of MGP may re-
flect the vitamin K status of cartilage and arteries.
Physiology of bone metabolism
Bone is a living tissue that undergoes continuous
turnover processes.Reconstruction comprises bone re-
sorption by matrix-degrading osteoclasts and bone for-
mation by matrix-forming osteoblasts. In the adult
skeleton, new bone formation is primarily the result of
bone remodelling.In both trabecular and cortical bone,
bone remodelling results from the coupled bone resorp-
tion/formation activity of bone remodelling units that
substitute old bone for new bone.Bone remodelling is a
life-long process needed to maintain the mechanical in-
tegrity of the skeleton.In young adults,bone resorption
and formation are coupled. Net bone resorption can
however occur due to an uncoupling of the bone forma-
tion  and resorption processes [28]. Skeletal integrity
mainly depends on mechanical loading. Consequently,
bone mass and strength are primarily influenced by me-
chanical forces. Except for trauma, muscle forces cause
the largest loads on bones and the largest bone strains
[29].
The threshold level for bone loss or bone accretion
can be influenced by various local and systemic factors,
known to modulate the bone remodelling process. In-
terestingly, up-regulation of pro-osteoclastogenic cy-
tokines such as interleukin 6 results in the stimulation of
bone resorption [30] and also promotes atherosclerosis
[31].During recent years various biomarkers of the ac-
tivity of osteoblasts and osteoclasts have become clini-
cally available [32]. Among them are collagen type I
propeptides and degradation products, which are re-
leased into the circulation.Assays for intact or total OC,
the most abundant noncollagenous protein in bone,are
commonly used to assess bone formation while as al-
ready mentioned it is now possible to separately assess
postranslational differences in the expression of cOC
and ucOC.Bone markers reflect changes in bone metab-
olism and can thus provide insights in the physiology
and pathophysiology of bone.
As expected, biomarkers of bone turnover are ad-
versely affected by immobilisation [33] and micrograv-
ity [34].However,the data obtained during spaceflights
also indicate that some of the changes in bone turnover
markers are not related to mechanical unloading but to
lack of vitamin K [35]. Moreover, circadian variations
[36], monthly fluctuations [30, 37] and a circannual
rhythm [38] have been observed in bone turnover
markers,which seem to be at least in part affected by dif-
ferences in vitamin D status,calcium supply,and fluctu-
ations in circulating sex hormones. All these observa-
tions are in line with the concept that the threshold
values for net bone loss or net bone formation are not
only influenced by mechanical loading or unloading of
the bone but also by various exogenous factors includ-
ing specific nutrients such as vitamin K.
Vitamin K is a potentially interesting contributory
factor in the regulation of bone remodelling.Apart from
the well-documented evidence linking under-carboxy-
lation of osteocalcin to low bone mass, a deficiency of
another Gla-protein, protein S, is also associated with
low bone mass [39]. The precise role of osteocalcin in
bone is still unknown. Osteocalcin-deficient mice ap-
peared to have larger bones than their wild-type litter-
mates,showing that osteocalcin is a negative regulator of
bone formation [40].On the other hand,the protein has328 European Journal of Nutrition (2004) Vol. 43, Number 6
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a role in the orderly deposition of hydroxyapatite,both
in growing bone and during bone remodelling. Finally,
the osteocalcin knock-out model showed strongly in-
creased bone loss after ovariectomy, suggesting a pro-
tective role for osteocalcin after menopause. In human
studies low serum vitamin K concentrations have been
found in patients with osteoporotic fractures [44, 45],
and the first randomised intervention studies indicate
that increasing vitamin K intake may help reduce post-
menopausal bone loss (see below).
MGP is of major importance to the prevention of pre-
mature calcification, and inhibits the deposition of ex-
tra-cellular calcium matrix in both cartilage and in arte-
rial vessel walls. MGP-deficient mice were normal at
birth, but developed massive calcifications in all large
arteries in the weeks thereafter [41]. All animals died
from rupture of the thoracic or abdominal aorta within
8 weeks after birth.The type of calcification in MGP-de-
ficient mice is comparable to that found in association
with aging and diabetes mellitus (also known as
Mönckeberg’s sclerosis) rather than to atherosclerosis.
Whereas atherosclerosis is a disease of the arterial in-
tima characterised by inflammation, macrophage infil-
tration, intima thickening and plaque formation,
Mönckeberg’s sclerosis is primarily a disease of the tu-
nica media characterised by calcifications starting
around the elastin fibers, followed by more elaborate
calcifium salt depositions and vascular damage.On the
basis of our present knowledge it is likely that increased
vitamin K intake may protect vascular health via im-
proved MGP carboxylation, and therefore may have a
protective effect against age-related vascular stiffening
rather than against classical atherosclerosis.The impor-
tance of vitamin K for bone and vascular health was also
demonstrated in rats using coumarin antagonists to
block vitamin K utilisation; in this model both bone
malformation and aortic calcification were observed
[42,43].
Vitamin K intake, bone mass and fracture risk
Several studies have reported the relationship between
vitamin K intake, bone mass, and hip fracture. The
Nurses’ Health Study recruited 72,327 women aged be-
tween 38 and 63 years,i.e.relatively young women who
have a markedly lower incidence of hip fracture than
elderly ones [46]. Their average baseline vitamin K
intake was 192 µg/day.During the ten-year study period,
there were 270 hip fractures (fracture inci-
dence=38.4/100,000 person-years). The study popula-
tion was further divided into quintiles,according to di-
etary vitamin K1 intake (Q1 received the lowest vitamin
K intake,Q5,the highest).The incidence of hip fracture
in women in Q2–Q5, relative to Q1, was lower, with a
multiple adjusted relative risk of 0.70 (95% CI:
0.53–0.93).When these women were examined accord-
ing to use of hormone replacement therapy (HRT) it was
found that vitamin K intake had no effect on the hip-
fracture risk of current or past HRT users.In contrast,it
had a significant protective effect on subjects who had
never used HRT (and were least protected against post-
menopausal osteoporosis).Subjects in Q1 showed an in-
cidence of 81.8 fractures per 100,000 person-years,
whilst subjects in Q2–Q5 reported a much lower inci-
dence of 54.8.
The Framingham study investigated vitamin K intake
in older women (average age 75 years),in whom the av-
erage dietary vitamin K1 intake was 155 µg/day [47].
There was no significant correlation between dietary K1
intake and either bone mineral density (BMD) or bone
loss. However, when the cohort was divided into quar-
tiles according to K1 intake (Q4=highest K1 intake),
there was a significant reduction in hip fracture risk for
Q4,compared to Q1 (RR=0.35; 95% CI: 0.13–0.94).The
authors concluded that vitamin K has a more pro-
nounced effect on fracture than on BMD, and that di-
etary vitamin K intakes below 109µg/d are associated
with increased hip fracture risk.In another study in the
Framingham Offspring cohort among younger women
and men (average ages: 59 and 58 years respectively)
there was a positive correlation between K1 intake and
BMD in women but not in men [48].However in men,a
positive correlation was found between BMD and blood
parameters of vitamin K status (serum K1 and ucOC)
[49]. The physiological significance of this discordance
between men and women remains to be elucidated.
Natto is a fermented soybean food particularly ap-
preciated in eastern Japan (e.g. Tokyo), and it is ex-
tremely rich in vitamin K (notably MK-7).In a Japanese
study,postmenopausal women in areas with a tradition-
ally high natto intake were compared with women from
western Japan (e.g. Hiroshima) where natto is not a
common food.It was found that natto consumption was
associated with markedly elevated serum levels of MK-
7. Interestingly, hip fracture incidence is markedly
higher in western Japan than in eastern Japan [50].
Thus, it was suggested that the high intake of natto-de-
rived MK7 contributes to the lower hip fracture inci-
dence in eastern Japan. Other studies investigated hip
fracture incidence in two other populations.Elderly in-
stitutionalised persons have a much lower vitamin K
and vitamin D intake and a much higher hip fracture
risk as compared with home-dwellers,and several stud-
ies have identified low vitamin K intake as an indepen-
dent risk factor [51,52].
Whereas all these population-based studies provide
an accumulating amount of evidence for high vitamin K
intake as an independent factor decreasing the risk of
postmenopausal osteoporosis and hip fracture,method-
ological imperfections and potential confounders mean
that no firm conclusions can be drawn. Dietary ques-C. Vermeer et al. 329
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tionnaires allow an evaluation ofrecent vitamin K intake
whereas it is difficult to evaluate average intake over a
life-time.In some cohort studies,evaluation of vitamin
K intake has been repeated at different ages;however at-
trition of the less healthy and less dietary aware can re-
sult in a non-representative population.A high vitamin
K intake usually depends on a high consumption of
green vegetables and is often associated with a healthier
lifestyle.Thus,final proof for the importance of vitamin
K in bone health must come from well-designed inter-
vention trials.Last but not least,mechanistic studies are
needed to delineate the role of vitamin K and Gla-pro-
teins in bone physiology at the molecular level.
Osteocalcin carboxylation, bone mass 
and fracture risk
The original stimulus for studying the relationship be-
tween dietary intakes of vitamin K and bone health had
been some small patient-based studies suggesting a pos-
sible link between low serum K1 and osteoporosis [44,
45] and even more convincing epidemiological evidence
obtained by Szulc and co-workers showing a positive as-
sociation between ucOC and fracture risk [25, 57] and
an inverse association between ucOC and bone mass
[26] in French elderly women. Another prospective
study performed in elderly home-dwelling French
women (EPIDOS) showed an increased hip fracture risk
in the highest quartile of serum ucOC [58]. Similar as-
sociations linking an impaired carboxylation ofOC with
bone mass and fracture risk were subsequently reported
from The Netherlands [22] and Finland [59].Since,as al-
ready discussed,the carboxylation of OC is sensitive to
vitamin K intakes in the usual dietary range,these asso-
ciations with ucOC give credence to the hypothesis that
adequate intakes of vitamin K are necessary to maintain
healthy bones. Lately, this hypothesis has been rein-
forced by studies of patients with chronic gastrointesti-
nal disorders in whom malabsorption of fat-soluble vit-
amins is common. Thus patients with primary biliary
cirrhosis and Crohn’s disease are known to be at high
risk of osteoporosis and often have both low serum K1
concentrations and a high circulating ucOC [53–56].Im-
portantly, the study by Schoon etal. [53] provided evi-
dence of an inverse relationship between ucOC and
BMD in Crohn’s disease.
Vitamin K1 intervention studies for bone health
The Dundee Bones and Vitamins Intervention Study (D-
BAVIS) was a two-year intervention study involving vit-
amin K1,vitamin D,and calcium [60].The study aimed
to determine whether vitamin K1 and/or vitamin D plus
calcium favourably influenced BMD in healthy older
women,and whether vitamins K1 and D had a synergis-
tic effect on bone health outcomes. 244 women aged
60–87 years were recruited stratified by age into the
study and randomly assigned to one of four supplement
groups: [1] placebo,[2] vitamin K1 200 µg/day,[3] vita-
min D3 10 µg/day and calcium 1g/day, and [4] vitamin
D3 10 µg/day and calcium 1g/day, and vitamin K1 200
µg/day.Subjects were followed-up every six months with
DXA bone scans,biochemical markers of bone turnover
and serum 25-OH vitamin D and separate Glu and Gla-
osteocalcin measurements for vitamin D and K status,
respectively.I n summary, the results were (i) there was
evidence of sub-optimal vitamin D and K status at base-
line,(ii) supplementation with vitamin D and vitamin K
significantly raised serum 25-OH vitamin D and cOC
concentrations, respectively, indicating improved vita-
min status, (iii) vitamin D supplementation had no in-
fluence on gamma-carboxylation of osteocalcin,(iv) the
sum of ucOC and cOC increased from baseline in all
groups equivalently,(v) neither cross-linked N-telopep-
tides (NTX) nor bone-specific alkaline phosphatase
(BAP) changed over time or between supplement
groups, (vi) relative to baseline, there was a significant
increase in bone mineral content and areal density at the
ultra-distal radius site in the combined calcium plus
vitamins K and D supplemented group,(vii) significant
bone mineral loss only occurred at the mid-distal radius
site, equivalent for all groups, and (viii) no significant
loss occurred at the hip sites for any group (including
placebo).The authors concluded that combined supple-
mentation with vitamins K1 and D3 at dietary relevant
intakes significantly improved BMD at the highest tra-
becular bone site measured,and that equivalent supple-
mentation in high osteoporotic risk groups may be ben-
eficial.
In the Maastricht osteostudy 188 postmenopausal
women aged 50–60 years were recruited,and treated for
three years with daily supplements [61].The first group
received placebo (maltodextrine), the second received
minerals (500mg/day calcium,150mg/day magnesium,
and 10mg/day zinc) and 8 µg/day vitamin D3,a n d  t h e
third group received minerals plus vitamin D3 and an
additional 1mg/day of vitamin K1. Optimal osteo-pro-
tective effects were obtained at the site of the femoral
neck if vitamin K was used in combination with mine-
rals and vitamin D.Although no complete prevention of
bone loss was achieved, the rate of bone loss had de-
creased by 35–40% as compared to the placebo and
minerals plus vitamin D groups. It may be calculated
that if the observed effects continue over decades, life-
long supplementation could postpone fractures by up to
ten years.330 European Journal of Nutrition (2004) Vol. 43, Number 6
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Vitamin K1 intervention studies for vascular health
Accumulating evidence suggests that in many aspects
arterial calcification mimics bone formation, which
prompts interest in the effects of vitamin K on the vas-
culature. Previous population-based studies reported a
significant reduction in aortic calcification with high
vitamin K1[62] and vitamin K2intake [63],and a signifi-
cant inverse correlation was found between vitamin K2
intake, and the incidence of both ischaemic heart dis-
ease and cardiovascular mortality [63]. Based on these
findings the effect of treatment on arterial characteris-
tics was monitored in the Maastricht osteostudy. These
unpublished findings clearly demonstrated that supple-
mentation with vitamin K1 can protect against vascular
hardening and loss of arterial elasticity.High dose MK-
4 also seems to have cholesterol lowering properties as
shown in studies in rabbits [64] and humans [65].
MK-4 intervention studies for bone health
Extremely high doses (45–90mg/day) of MK-4 have
been used for the treatment of postmenopausal osteo-
porosis in Japan for several years [66,67].After the pos-
itive outcomes of the first clinical trials, the treatment
is now used on a large scale; thus far, no adverse side-
effects have been reported. A number of independent
groups have claimed that this medication results in
complete prevention of further bone loss in post-
menopausal women,and in some women even a signif-
icant gain in BMD [68, 69]. The treatment was also re-
ported to be successful in other groups at risk for bone
loss such as haemodialysis patients and those treated
with corticosteroids.It remains to be seen whether sim-
ilar beneficial effects of high MK-4 intake will be ob-
served outside Japan for populations whose predisposi-
tion to osteoporosis differs with respect to hereditary
factors as well as lifestyle factors such as calcium in-
takes.
Potential adverse effects of vitamin K-antagonists
(oral anticoagulants)
Vitamin K-antagonists are frequently used in the treat-
ment and prevention of thromboembolic events. Their
mode of action is that they interfere with the recycling
of vitamin K-epoxide into the quinone form and thus
rapidly deplete the vitamin K stores. During recent
years, conflicting data have been reported on whether
subjects on long-term oral anticoagulant treatment have
low bone mass and increased risks for osteoporosis and
fractures [70–74]. In a recent meta-analysis, Caraballo
etal.concluded that long-term oral anticoagulation may
be associated with a modestly increased bone fragility
and osteoporotic fracture risk [75]. Most studies pub-
lished thus far are retrospective and lack good control
populations, however. Since anticoagulated patients
form a diseased population which may differ from the
general population in many aspects (lower mobility,
more controlled diet, lower body mass index) these
studies are not easy to interpret.At this time bone den-
sitometry measurements or fracture risk assessment in
a prospective randomised study in which subjects are
anticoagulated with either coumarin-type (vitamin K-
antagonists) or aspirin-type drugs has not yet been pub-
lished.
A second potential adverse effect of oral anticoagu-
lants is that they may promote vascular calcification.In
animal model systems severe calcification has been re-
ported after a relatively short treatment with warfarin
[43,76].Remarkably,the warfarin-induced artery calci-
fication could be completely blocked by vitamin K2,but
not vitamin K1,suggesting a more prominent role for K2
vitamins in the vasculature [76].
Immunological basis for high-dose vitamin K
The daily amounts of MK-4 administered in Japan as a
prophylactic therapeutic agent are greatly in excess of
those required to normalize gamma-carboxylation of
vitamin K-dependent bone proteins,suggesting the pos-
sibility of alternative mechanisms of action in this spe-
cific use. Under normal dietary and physiological con-
ditions, vitamin K is mainly catabolised by hepatic
metabolism involving side chain shortening (most
probably by the mitochondrial β-oxidation pathway) to
two major urinary aglycones, a 5-carbon and 7-carbon
carboxylic acid product with the 5-carbon metabolite
predominating.The same two aglycones are excreted in
greater amounts after the administration of pharmaco-
logical doses of K1,MK-4 and MK-7 showing that there
is a common pathway of catabolism for K vitamins [20,
77].Whether the same oxidative degradation of vitamin
K takes place in non-hepatic tissues is not known but the
increased generation of vitamin K catabolites per se
might explain some of the observed therapeutic effects
of high-dose vitamin K intervention in ameliorating
bone loss. It has been shown using cytohistochemistry
that β-hydroxyacyl dehydrogenase activity (an enzyme
of β-oxidation) is increased during bone resorption
[78], suggesting the possibility that the catabolites of
vitamin K exert unexpected biological activities. It has
been shown, for instance, that in a rat paw oedema
model the 7-carbon carboxylic acid catabolite of vita-
min K has potent anti-inflammatory activity [79] medi-
ated by modulation of cytokines [80].
It is widely appreciated that leukocytes can release a
range of pro- and anti-inflammatory cytokines. Other
cells can also release cytokines,including cells in bone,C. Vermeer et al. 331
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which  are in constant contact with the cells in the
haemopoietic compartment,including,of course,leuko-
cytes. Recent data have shown that the osteoblast-like
cell line MG63 can be induced to release interleukin-6
(IL-6) in the presence of lipopolysaccharide (LPS) or
1,25(OH)2vitamin D3 [81]. Furthermore, IL-6 has been
recognised as a potent activator of bone resorption by
inducing osteoclastogenesis [82]. Therefore, conditions
that cause increased levels of IL-6 may increase bone re-
sorption and decrease bone formation,whereas factors
that suppress IL-6 may be expected to interrupt the bio-
logical pathways that lead to increased bone loss.
When the osteosarcoma MG-63 cell-line is chal-
lenged with LPS it can be induced to release IL-6 thus
providing a cell model to investigate the biological prop-
erties of the vitamin K metabolites.If MG63 cells are co-
challenged with LPS (from E. coli) and the 5-carbon
vitamin K catabolite, an inhibition of IL-6 release was
observed at high concentrations of this compound (10–5
M). However, the 7-carbon carboxylic acid catabolite
was found to be a much more potent inhibitor ofLPS-in-
duced IL-6 release by MG63 cells in culture (10–7 – 10–8
M) [74]. This observation suggests the possibility that
administration of high doses of vitamin K may also act
on the skeleton through a modulation of cytokine-me-
diated events. In high dose vitamin K regimens the ac-
tive 7-carbon carboxylic acid vitamin K catabolite may
be able to prevent bone resorption by inhibiting cy-
tokine-mediated osteoclastogenesis,and facilitate bone
formation, while the vitamin K itself will ensure com-
plete gamma-carboxylation of the vitamin K-dependent
proteins in bone. Although speculative, the possibility
that vitamin K may modulate physiological responses
through manipulation of cytokine networks suggests a
potentially interesting hypothesis and a novel avenue of
research for therapeutic intervention in metabolic bone
disease.
Which is the most important vitamin, K1 or K2?
There is no conclusive evidence that at nutritionally rel-
evant doses, the physiological functions of vitamins K1
and K2 are different: both are capable of functioning as
a cofactor for the gamma-glutamyl carboxylase,and dif-
ferences may only be expected with respect to pharma-
cokinetics and tissue distribution.This may be the rea-
son why some menaquinones seem to have a greater
effect in preventing arterial calcification than K1.In the
western diet, K1 from green vegetables forms around
80% of the total vitamin K intake, but because of low
bioavailability their contribution to total vitamin K sta-
tus is likely to be over-estimated: vitamin K1 from spe-
cific vegetable oils may be more efficacious, but more
work is required in this area. If the potential specific
anti-atherosclerotic effects of menaquinones are con-
firmed,then increased consumption of certain MK-con-
taining foods (or high-MK food extracts or pure supple-
ments) may be beneficial to health.
The only synthetic forms of vitamin K that are avai-
lable for use in humans are K1and MK-4;both forms are
well-absorbed.Published clinical trials with MK-4 have
invariably used high doses (45–90mg/day),whilst K1has
been tested at relatively low doses. K1 is the analogue
used in nearly all K-containing food supplements and
multivitamin preparations available on the western
market. Nutritionally relevant doses are generally con-
siderably less than 1mg/day; unfortunately, no MK-4
studies have been published at or below this dose.Phar-
macological doses of MK-4 are typically 45mg/day,and
no studies have been carried out with K1 at this dosage
level.Differences may become clearer if both analogues
are used at comparable levels,and stronger comparisons
could be made at dietary intakes up to 1mg/day as well
as at pharmacological doses up to 100mg/day.Based on
the available literature it is not yet possible to evaluate
the efficacies of vitamins K1 and MK-4 at similar dosage
levels, and the execution of new, comparative trials
should be encouraged.Bone and arterial vessel wall are
potential target tissues for increased vitamin K intake,
and both have the remarkable capacity to convert K1
into MK-4 under physiological conditions [4]. To date
there are no compelling clinical reasons to favour one
vitamin K analogue over another, but from a dietary
viewpoint,it may be preferable to investigate K1.
In considering the potential efficacy of pharmaco-
logical doses of MK-4 it should be noted that there is ev-
idence for a secondary function of this analogue over
and above its role in glutamate carboxylation.The avai-
lable evidence (mainly from cell culture experiments)
suggests that MK-4 (but not K1) may also be associated
with production of interleukin-6,regulate the synthesis
of PGE2 [83], or inhibit the mevalonate pathway in a
comparable way to bisphosphonates [84],but at present
only preliminary data exist. Below we will restrict our-
selves to the potential benefit of nutritionally relevant
doses of vitamin K.
Consideration of recommended and supplemental
levels of vitamin K in context to EU legislation
There is a growing awareness that vitamin K adequacy
alone,and particularly when used as a food supplement,
may have little effect on bone health if other nutrient in-
adequacies exist.Similarly,the long-term benefit of sup-
plements containing only calcium and vitamin D is not
always obvious:such supplements may show a transient
effect on bone, but in studies of ≥3 years the beneficial
effect relative to placebo is often lost [85].Emerging data
suggest that vitamin K supplements should also contain
calcium and vitamin D,and perhaps other minerals such332 European Journal of Nutrition (2004) Vol. 43, Number 6
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as magnesium and zinc to have optimal osteogenic ef-
fects.
Dietary Adequate Intake (AI) values have only been
defined in a limited number of countries,and are based
on the intakes of vitamin K1 needed to maintain hepatic
synthesis of blood coagulation factors. The current
guideline in the UK is 1µg/day/kg body weight [86].Av-
erage values for dietary vitamin K intake range from
around 60–70µg/day in several British and American
studies [19, 87–89] to 245 µg/day in The Netherlands, a
country known for high green vegetable intake. In all
studies green vegetables were the main food source.
Most studies report that one-half of the populations in-
vestigated had daily vitamin K intakes below the present
guidelines.Based on consideration of bone and vascular
health,there are as yet insufficient data to define tolera-
ble upper limits, recommended daily intakes, or to dis-
tinguish between K1 and K2 requirements.
The bioavailability ofvitamin K1from supplements is
probably greater than that from most foods (e.g.possi-
bly between 3 to 5 fold higher than that from green veg-
etables); hence the dietary-equivalent bioavailable K1
from the supplements consumed,for example,by the D-
BAVIS population is presumed to have been greater than
200 µg/d. Evidence from the Framingham study indi-
cated that there was an increased risk of fracture at in-
takes below 109 µg/day.These data suggest that further
studies are required to evaluate both the efficacy of
higher food-based intakes and those of smaller supple-
mental doses,of the order of 100 µg/day before optimal
intakes for bone health can be clarified. In the mean-
time, it seems fairly clear that higher dietary intakes
than those generally consumed would be beneficial and
that supplemental levels of around 100 µg/day would
also improve vitamin K status in the majority ofthe pop-
ulation. European legislation exists defining the maxi-
mum supplementary dose of vitamin K1 which can be
administered,and in most countries,the addition of 100
µg/day is already allowed. The possibility for this to be
increased by up to 50% exists,if supportive clinical evi-
dence were available.Currently in the EU countries syn-
thetic MK-4 is not allowed as a food supplement because
the supporting evidence for its independent role in
health does not exist.The alternative routes for obtain-
ing K2 from the food chain are through eating natto
(MK-7), cheeses (mainly MK-9) and menadione pro-
vided in animal feed,which enriches meat and eggs.
Any risks associated with relatively high consump-
tion of either K1 or K2 appear minimal,with intakes up
to 1mg/d K1 and 45mg/d MK-4 often having been used
without observed adverse events. Two possible excep-
tions exist. Firstly a potential problem relates to inter-
ference with oral anticoagulants.However,a systematic
dose-response study among subjects on oral anticoagu-
lant treatment demonstrated that the stability of antico-
agulation was not significantly affected by vitamin K
supplements at doses below 100 µg/day [14]. Secondly,
preliminary studies have suggested that high vitamin K1
supplementation (i.e.above 1mg/day) can contribute to
periodontal disease via a bacterial mechanism on gingi-
val tissue (S.Hodges,unpublished data).
Conclusions
From the available dietary data, it would appear that
daily intakes of between 200 and 500µg/d of dietary
vitamin K may be required for optimal gamma-car-
boxylation of OC, which may in turn benefit bone
health. Available evidence of relative bioavailabilities
suggests that the same benefits may be achieved with
lower intakes of supplements, which need to be deter-
mined but may be of the order of 100 µg/d. There is
growing evidence to suggest that vitamin K may be act-
ing synergistically with vitamin D,calcium and possible
other micronutrients to maximally influence bone min-
eral accretion and potentially inhibit vascular calcifica-
tion.As such, health benefits may accrue from supple-
mental vitamin K being combined with vitamin D and
minerals. Considerably more work is required in the
area of vitamin K including understanding relative
bioavailability, optimal tissue-specific status indicators
and the relative importance of gamma-carboxylation
status to the growing number of health outcomes that
may be influenced by vitamin K inadequacy.
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